By Cecilia Butini

 

Sanofi SA said Friday that the Covid-19 vaccine program it is developing with British pharmaceutical giant GlaxoSmithKline PLC has experienced a delay.

The French pharmaceutical major said the program was to improve immune response in the elderly, but Phase 1-2 interim results showed insufficient immune response in that group.

Sanofi said the reason for the low immune response was probably an insufficient concentration of the antigen utilized, and that the two companies are planning a new study with an improved antigen formulation to start in February 2021.

The vaccine is now expected to become available in the fourth quarter of 2021, pending completion of the development plan.

 

Write to Cecilia Butini at cecilia.butini@wsj.com

 

(END) Dow Jones Newswires

December 11, 2020 01:40 ET (06:40 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
過去 株価チャート
から 2 2024 まで 3 2024 Gskのチャートをもっと見るにはこちらをクリック
Gsk (LSE:GSK)
過去 株価チャート
から 3 2023 まで 3 2024 Gskのチャートをもっと見るにはこちらをクリック